Thermal potentiation of chemotherapy by magnetic nanoparticles

Nanomedicine

Volumn 8, Issue 10, 2013, Pages 1689-1707

  Torres Lugo, Madeline ^a   Rinaldi, Carlos ^b  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b University of Florida   (United States)

Author keywords

magnetic fluid hyperthermia; magnetic nanoparticle; synergy; thermal potentiation

Indexed keywords

8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; FLAVONOID; FLUOROURACIL; GELDANAMYCIN; GEMCITABINE; GIMERACIL; GOLD NANOPARTICLE; IFOSFAMIDE; IRINOTECAN; MAGNETIC NANOPARTICLE; MITOMYCIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; OXALIPLATIN; PACLITAXEL; SARCOLYSIN; TANESPIMYCIN; TERT BUTYL HYDROPEROXIDE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ANISOTROPY; ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BREAST ADENOCARCINOMA; CANCER THERAPY; CANCER TISSUE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; CLINICAL FEATURE; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG DELIVERY SYSTEM; DRUG UPTAKE; EXTRACELLULAR MATRIX; FEVER; FOOD AND DRUG ADMINISTRATION; HEAT TRANSFER; HEAT TREATMENT; HELA CELL; HUMAN; HYDRODYNAMICS; HYPERTHERMIA; HYPERTHERMIC THERAPY; IN VITRO STUDY; IN VIVO STUDY; INFRARED RADIATION; LEWIS CARCINOMA; LIFESPAN; LIVER CELL CARCINOMA; LYSOSOME MEMBRANE; MAGNETIC FIELD; MELANOMA B16; MICROWAVE RADIATION; MULTIPLE MYELOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PANCREAS CANCER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN UNFOLDING; RADIOFREQUENCY; RELAXATION TIME; REVIEW; SURVIVAL RATE; TRANSITION TEMPERATURE; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

CHEMOTHERAPY, ADJUVANT; FERRIC COMPOUNDS; HUMANS; HYPERTHERMIA, INDUCED; MAGNETITE NANOPARTICLES; MODELS, THEORETICAL; NEOPLASMS; TEMPERATURE;

EID: 84885108081     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.146     Document Type: Review

References (169)

1. Cornell RM, Schwertmann U The Iron Oxides: Structure, Properties, Reactions, Occurrences and Uses (2nd Edition). Wiley VCH Verlag GMBH & Co, Weinheim, Germany (2003).
2. Spaldin NA. Magnetic Materials: Fundamentals and Applications (2nd Edition). Cambridge University Press, NY, USA (2010).
3. Russel WB, Saville DA, Schowalter WR. Colloidal Dispersions. Cambridge University Press, Cambridge, UK (1989).
4. Jordan A, Scholz R, Wust P, Fähling H, Felix R. Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J. Magn. Magn. Mater. 201(1), 413-419 (1999).
5. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18), 3995-4021 (2005).
6. Dennis CL, Jackson AJ, Borchers JA et al. Nearly complete regression of tumors via collective behavior of magnetic nanoparticles in hyperthermia. Nanotechnology 20(39), 395103 (2009).
7. Giustini AJ, Ivkov R, Hoopes PJ. Magnetic nanoparticle biodistribution following intratumoral administration. Nanotechnology 22(34), 345101 (2011).
8. Khot VM, Salunkhe AB, Thorat ND, Ningthoujam RS, Pawar SH. Induction heating studies of dextran coated MgFe2O4 nanoparticles for magnetic hyperthermia. Dalton Trans. 42(4), 1249 (2012).
9. Kut C, Zhang Y, Hedayati M et al. Preliminary study of injury from heating systemically delivered, nontargeted dextran-superparamagnetic iron oxide nanoparticles in mice. Nanomedicine 7(11), 1697-1711 (2012).
10. Easo SL, Mohanan PV. Dextran stabilized iron oxide nanoparticles: Synthesis, characterization and in vitro studies. Carbohydr. Polym. 92(1), 726-732 (2013).
11. Herrera AP, Barrera C, Rinaldi C. Synthesis and functionalization of magnetite nanoparticles with aminopropylsilane and carboxymethyldextran. J. Mater. Chem. 18(31), 3650-3654 (2008).
12. Creixell M, Herrera AP, Latorre-Esteves M, Ayala V, Torres-Lugo M, Rinaldi C. The effect of grafting method on the colloidal stability and in vitro cytotoxicity of carboxymethyl dextran coated magnetic nanoparticles. J. Mater. Chem. 20(39), 8539-8547 (2010).
13. López-Cruz A, Barrera C, Calero-DdelC VL, Rinaldi C. Water dispersible iron oxide nanoparticles coated with covalently linked chitosan. J. Mater. Chem. 19(37), 6870-6876 (2009).
14. Wang J, Zhao G, Li Y, Liu X, Hou P. Reversible immobilization of glucoamylase onto magnetic chitosan nanocarriers. Appl. Microbiol. Biotechnol. 97(2), 681-692 (2012).
15. Hoque SM, Srivastava C, Srivastava N, Venkateshan N, Chattopadhyay K. Synthesis and characterization of Fe- and Co-based ferrite nanoparticles and study of the T1 and T2 relaxivity of chitosan-coated particles. J. Mater. Sci. 48(2), 812-818 (2012).
16. Unsoy G, Yalcin S, Khodadust R, Gunduz G, Gunduz U. Synthesis optimization and characterization of chitosan-coated iron oxide nanoparticles produced for biomedical applications. J. Nanopart. Res. 14(11), 964 (2012).
17. Sonvico F, Mornet S, Vasseur S et al. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro experiments. BioconJ. Chem. 16(5), 1181-1188 (2005).
18. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J. Biomed. Mater. Res. Part A 78A(3), 550-557 (2006).
19. Barrera C, Herrera A, Zayas Y, Rinaldi C. Surface modification of magnetite nanoparticles for biomedical applications. J. Magn. Magn. Mater. 321(10), 1397-1399 (2009).
20. Barrera C, Herrera AP, Rinaldi C. Colloidal dispersions of monodisperse magnetite nanoparticles modified with poly(ethylene glycol). J. Colloid Interface Sci. 329(1), 107-113 (2009).
21. Barrera C, Herrera AP, Bezares N et al. Effect of poly(ethylene oxide)-silane graft molecular weight on the colloidal properties of iron oxide nanoparticles for biomedical applications. J. Colloid Interface Sci. 377(1), 40-50 (2012).
22. Bee A, Massart R, Neveu S. Synthesis of very fine maghemite particles. J. Magn. Magn. Mater. 149(1), 6-9 (1995).
23. Halbreich A, Roger J, Pons JN et al. Biomedical applications of maghemite ferrofluid. Biochimie 80(5), 379-390 (1998).
24. RuizMoreno RG, Martinez AI, Castro-Rodriguez R, Bartolo P. Synthesis and characterization of citrate coated magnetite nanoparticles. J. Supercond. Nov. Magn. 26(3), 709-712 (2012).
25. Ruizmoreno RG, Martínez AI, Falcony C, Castro-Rodriguez R, Bartolo-Pérez P, Castro Román M. One pot synthesis of water compatible and monodisperse magnetite nanoparticles. Mater. Lett. 92(C), 181-183 (2013).
26. Fauconnier N, Pons JN, Roger J, Bee A. Thiolation of maghemite nanoparticles by dimercaptosuccinic acid. J. Colloid Interface Sci. 194(2), 427-433 (1997).
27. Huang H, Delikanli S, Zeng H, Ferkey DM, Pralle A. Remote control of ion channels and neurons through magnetic-field heating of nanoparticles. Nat. Nanotechnol. 5(8), 602-606 (2010).
28. Xiong F, Zhu ZY, Xiong C et al. Preparation, characterization of 2-deoxy-d-glucose functionalized dimercaptosuccinic acid-coated maghemite nanoparticles for targeting tumor cells. Pharm. Res. 29(4), 1087-1097 (2011).
29. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. Specific targeting of folate dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magn. Reson. Mater. Phys. Biol. Med. 12(2-3), 104-113 (2001).
30. Yoo MK, Park IK, Lim HT et al. Folate-PEG-superparamagnetic iron oxide nanoparticles for lung cancer imaging. Acta Biomater. 8(8), 3005-3013 (2012).
31. Mahajan S, Koul V, Choudhary V, Shishodia G, Bharti AC. Preparation and in vitro evaluation of folate-receptor-targeted SPION-polymer micelle hybrids for MRI contrast enhancement in cancer imaging. Nanotechnology 24(1), 015603 (2012).
32. Ahrens ET, Feili-Hariri M, Xu H, Genove G, Morel PA. Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn. Reson. Med. 49(6), 1006-1013 (2003).
33. Grüttner C, Müller K, Teller J, Westphal F, Foreman A, Ivkov R. Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. J. Magn. Magn. Mater. 311(1), 181-186 (2007).
34. Le B, Shinkai M, Kitade T et al. Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J. Chem. Eng. Jap. 34(1), 66-72 (2001).
35. Yang L, Mao H, Wang YA et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 5(2), 235-243 (2008).
36. Creixell M, Herrera AP, Ayala V et al. Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells. J. Magn. Magn. Mater. 322(15), 2244-2250 (2010).
37. Creixell M, Bohórquez AC, Torres-Lugo M, Rinaldi C. EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. ACS Nano 5(9), 7124-7129 (2011).
38. Wang AZ, Bagalkot V, Vasilliou CC et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 3(9), 1311-1315 (2008).
39. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 7(15), 2241-2249 (2011).
40. Bamrungsap S, Shukoor MI, Chen T, Sefah K, Tan W. Detection of lysozyme magnetic relaxation switches based on aptamer functionalized superparamagnetic nanoparticles. Anal. Chem. 83(20), 7795-7799 (2011).
41. Bamrungsap S, Chen T, Shukoor MI et al. Pattern recognition of cancer cells using aptamer-conjugated magnetic nanoparticles. ACS Nano 6(5), 3974-3981 (2012).
42. Auerbach M. Ferumoxytol as a new, safer, easier-to-ad minister intravenous iron: Yes or no? Am. J. Kidney Dis. 52(5), 826-829 (2008).
43. Marincek B. Diagnostic improvement in MRI of gynecological neoplasms. J. Belge Radiol. 79(1), 13-17 (1996).
44. Reimer P, Balzer T. Ferucarbotran (Resovist): A new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: Properties, clinical development, and applications. Eur. Radiol. 13(6), 1266-1276 (2003).
45. Sun C, Lee J, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Del. Rev. 60(11), 1252-1265 (2008).
46. Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv. Mater. 21(21), 2133-2148 (2009).
47. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaria J. Magnetic nanoparticles for drug delivery. Nano Today 2(3), 22-32 (2007).
48. Mcbain SC, Yiu HHP, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int. J. Nanomedicine 3(2), 169 (2008).
49. Tietze R, Lyer S, Dürr S, Alexiou C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (Lond.) 7(3), 447-457 (2012).
50. Wang N, Guan Y, Yang L et al. Magnetic nanoparticles (MNPs) covalently coated by PEO-PPO-PEO block copolymer for drug delivery. J. Colloid Interface Sci. 395(C), 50-57 (2013).
51. Pankhurst QA, Thanh NTK, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J. Phys. D Appl. Phys. 42(22), 224001 (2009).
52. Schwerdt JI, Goya GF, Calatayud P, Hereñú CB, Reggiani PC, Goya RG. Magnetic field-assisted gene delivery: Achievements and therapeutic potential. Curr. Gene Ther. 12(2), 116-126 (2012).
53. Mannix RJ, Kumar S, Cassiola F et al. Nanomagnetic actuation of receptor-mediated signal transduction. Nat. Nanotechnol. 3(1), 36-40 (2007).
54. Dobson J. Remote control of cellular behaviour with magnetic nanoparticles. Nature Nanotechnol. 3, 139-143 (2008).
55. Lee JH, Kim ES, Cho MH et al. Artificial control of cell signaling and growth by magnetic nanoparticles. Angew Chem. Int. Ed. 49(33), 5698-5702 (2010).
56. Sniadecki NJ. Minireview: A tiny touch: Activation of cell signaling pathways with magnetic nanoparticles. Endocrinology 151(2), 451-457 (2010).
57. Cho MH. A magnetic switch for the control of cell death signalling in in vitro and in vivo systems. Nat. Mater. 11(12), 1038-1043 (2012).
58. Derfus AM, von Maltzahn G, Harris TJ et al. Remotely triggered release from magnetic nanoparticles. Adv. Mater. 19(22), 3932-3936 (2007).
59. Amstad E, Kohlbrecher J, Müller E, Schweizer T, Textor M, Reimhult E Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. Nano Lett. 11(4), 1664-1670 (2011).
60. Hu SH, Chen YY, Liu TC, Tung TH, Liu DM, Chen SY. Remotely nano-rupturable yolk/shell capsules for magnetically-triggered drug release. Chem. Commun. 47(6), 1776 (2011).
61. Amstad E, Reimhult E. Nanoparticle actuated hollow drug delivery vehicles. Nanomedicine 7(1), 145-164 (2012).
62. Dennis CL, Jackson AJ, Borchers JA et al. The influence of collective behavior on the magnetic and heating properties of iron oxide nanoparticles. J. Appl. Phys. 103(7), 07A319 (2008).
63. Latorre M, Rinaldi C. Applications of magnetic nanoparticles in medicine: Magnetic fluid hyperthermia. PR Health Sci. J. 28(3), 227-238 (2009).
64. Laurent S, Dutz S, Häfeli UO, Mahmoudi M. Magnetic fluid hyperthermia: Focus on superparamagnetic iron oxide nanoparticles. Adv. Colloid Interface Sci. 166(1-2), 8-23 (2011).
65. Bickford LR. Ferromagnetic resonance absorption in magnetite single crystals. Phys. Review 78(4), 449-457 (1950).
66. Bickford LR, Brownlow JM, Penoyer RF. Magnetocrystalline anisotropy in cobalt-substituted magnetite single crystals. Proc. IEE-Part B Radio Electron. Eng. 104(5 Suppl.), 238-244 (1957).
67. Goya GF, BerquóTS, Fonseca FC, Morales MP. Static and dynamic magnetic properties of spherical magnetite nanoparticles. J. Appl. Phys. 94(5), 3520 (2003).
68. Del Castillo VLCD, Rinaldi C. Effect of sample concentration on the determination of the anisotropy constant of magnetic nanoparticles. IEEE Magn. Trans. 46(3), 852-859 (2010).
69. Tung LD, Kolesnichenko V, Caruntu D, Chou NH, O'Connor CJ, Spinu L. Magnetic properties of ultrafine cobalt ferrite particles. J. Appl. Phys. 93(10), 7486-7488 (2003).
70. Rosensweig RE. Heating magnetic fluid with alternating magnetic field. J. Magn. Magn. Mater. 252, 370-374 (2002).
71. Lee SW, Bae S, Takemura Y et al. Self-heating characteristics of cobalt ferrite nanoparticles for hyperthermia application. J. Magn. Magn. Mater. 310(2), 2868-2870 (2007).
72. Veverka M, Veverka P, Kaman O et al. Magnetic heating by cobalt ferrite nanoparticles. Nanotechnology 18(34), 345704 (2007).
73. Kim DH, Nikles DE, Johnson DT, Brazel CS. Heat generation of aqueously dispersed CoFe2O4 nanoparticles as heating agents for magnetically activated drug delivery and hyperthermia. J. Magn. Magn. Mater. 320(19), 2390-2396 (2008).
74. Lee JH, Jang JT, Choi JS et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat. Nanotechnol. 6(7), 418-422 (2011).
75. Simonsen LO, Harbak H, Bennekou P. Cobalt metabolism and toxicology - a brief update. Sci. Total Environ. 432(C), 210-215 (2012).
76. Fortin JP, Gazeau F, Wilhelm C. Intracellular heating of living cells through Néel relaxation of magnetic nanoparticles. Eur. Biophys. J. 37(2), 223-228 (2007).
77. Liu G, Hong RY, Guo L, Li YG, Li HZ. Preparation, characterization and MRI application of carboxymethyl dextran coated magnetic nanoparticles. Appl. Surf. Sci. 257(15), 6711-6717 (2011).
78. Lartigue L, Hugounenq P, Alloyeau D et al. Cooperative organization in iron oxide multi-core nanoparticles potentiates their efficiency as heating mediators and MRI contrast agents. ACS Nano 6(12), 10935-10949 (2012).
79. Nielsen OS, Horsman M, Overgaard J. A future for hyperthermia in cancer treatment? Eur. J. Cancer 37(13), 1587-1589 (2001).
80. Franckena M, van der Zee J. Use of combined radiation and hyperthermia for gynecological cancer. Curr. Opin. Obstet. Gynecol. 22(1), 9-14 (2010).
81. Pennacchioli E, Fiore M, Gronchi A. Hyperthermia as an adjunctive treatment for soft-tissue sarcoma. Expert Rev. Anticancer Ther. 9(2), 199-210 (2009).
82. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB. Selective inductive heating of lymph nodes. Ann. Surg. 146(4), 596-606 (1957).
83. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 65(1-2), 271-284 (2000).
84. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41(41), 189-207 (2001).
85. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Del. Rev. 63(3), 136-151 (2011).
86. Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. J. Control. Release 164(2), 108-114 (2012).
87. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J. Control. Release 161(2), 175-187 (2012).
88. Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. J. Control. Release 164(2), 138-144 (2012).
89. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J. Control. Release 164(3), 265-275 (2012).
90. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Del. Rev. 65(1), 71-79 (2013).
91. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 26(1), 74-85 (2008).
92. Gordon RT, Hines JR, Gordon D. Intracellular hyperthermia - biophysical approach to cancer-treatment via intracellular temperature and biophysical alterations. Med. Hypotheses 5(1), 83-102 (1979).
93. Rabin Y. Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? Int. J. Hyperthermia 18(3), 194-202 (2002).
94. Keblinski P, Cahill DG, Bodapati A, Sullivan CR, Taton TA. Limits of localized heating by electromagnetically excited nanoparticles. J. Appl. Phys. 100(5), 054305 (2006).
95. Andrä W, d'Ambly CG, Hergt R, Hilger I, Kaiser WA. Temperature distribution as function of time around a small spherical heat source of local magnetic hyperthermia. J. Magn. Magn. Mater. 194(1), 197-203 (1999).
96. Polo-Corrales L, Rinaldi C. Monitoring iron oxide nanoparticle surface temperature in an alternating magnetic field using thermoresponsive fluorescent polymers. J. Appl. Phys. 111(7), 07B334 (2012).
97. Rodriguez HL, Latorre-Esteves M, Mendez J et al. Enhanced reduction in cell viability by hyperthermia induced by magnetic nanoparticles. Int. J. Nanomedicine 6, 373-380 (2011).
98. Lee JS, Rodriguez-Luccioni HL, Méndez J et al. Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J. Nanosci. Nanotechnol. 11(5), 4153-4157 (2011).
99. Domenech M, Marrero-Berrios I, Torres Lugo M, Rinaldi C. Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. ACS Nano 7(6), 5091-5101 (2013).
100. Tuteja A, Mackay ME, Narayanan S, Asokan S, Wong MS Breakdown of the continuum stokes - Einstein relation for nanoparticle diffusion. Nano Lett. 7(5), 1276-1281 (2007).
101. Liao H, Nehl CL, Hafner JH. Biomedical applications of plasmon resonant metal nanoparticles. Nanomedicine 1(2), 201-208 (2006).
102. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med. Sci. 23(3), 217-228 (2007).
103. Lal S, Clare SE, Halas NJ. Nanoshell-enabled photothermal cancer therapy: Impending clinical impact. Acc. Chem. Res. 41(12), 1842-1851 (2008).
104. Strong LE, West JL. Thermally responsive polymer-nanoparticle composites for biomedical applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(3), 307-317 (2011).
105. Alkilany AM, Thompson LB, Boulos SP, Sisco PN, Murphy CJ. Gold nanorods: Their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Adv. Drug Del. Rev. 64(2), 190-199 (2012).
106. Mieszawska AJ, Mulder WJM, Fayad ZA, Cormode DP. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharm. 10(3), 831-847 (2013).
107. Jordan A, Scholz R, Maier-Hauff K et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia. J. Magn. Magn. Mater. 225(1), 118-126 (2001).
108. Hao R, Xing R, Xu Z, Hou Y, Gao S, Sun S. Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv. Mater. 22(25), 2729-2742 (2010).
109. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug Del. Rev. 62(3), 284-304 (2010).
110. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc. Chem. Res. 44(10), 875-882 (2011).
111. Xie J, Liu G, Eden HS, Ai H, Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc. Chem. Res. 44(10), 883-892 (2011).
112. Yiu HH. Engineering the multifunctional surface on magnetic nanoparticles for targeted biomedical applications: A chemical approach. Nanomedicine (Lond.) 6(8), 1429-1446 (2011).
113. Johannsen M, Gneveckow U, Taymoorian K et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective Phase I trial. Int. J. Hyperthermia 23(3), 315-323 (2007).
114. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin. Cancer Res. 7(8), 2168-2181 (2001).
115. Petin VG, Kim JK, Zhurakovskaya GP, Dergacheva IP. Some general regularities of synergistic interaction of hyperthermia with various physical and inactivating agents. Int. J. Hyperthermia 18(1), 40-49 (2002).
116. Greco WR, Bravo G, Parsons JC. The search for synergy - a critical-review from a response-surface perspective. Pharmacol. Rev. 47(2), 331-385 (1995).
117. Berenbaum MC. What is synergy. Pharmacol. Rev. 41(2), 93-141 (1989).
118. Kapinga HH. Cell biological effects of hyperthermia alone or combined with radiation or drugs: A short introduction to newcomers in the field. Int. J. Hyperthermia 22(3), 191-196 (2006).
119. Roti Roti JL. Cellular responses to hyperthermia (40-46 degrees C): Cell killing and molecular events. Int. J. Hyperthermia 24(1), 3-15 (2008).
120. Hauck TS, Jennings TL, Yatsenko T, Kumaradas JC, Chan WCW. Enhancing the toxicity of cancer chemotherapeutics with gold nanorod hyperthermia. Adv. Mater. 20(20), 3832-3838 (2008).
121. Issels RD. Hyperthermia adds to chemotherapy. Eur. J. Cancer 44(17), 2546-2554 (2008).
122. Ohtsubo T, Saito H, Tanaka N et al. Enhancement of cisplatin sensitivity and platinum uptake by 40 degrees C hyperthermia in resistant cells. Cancer Lett. 119(1), 47-52 (1997).
123. Takemoto M, Kuroda M, Urano M et al. The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int. J. Hyperthermia 19(2), 193-203 (2003).
124. van Bree C, Franken NA, Snel FA, Haveman J, Bakker PJ. Wild-type p53-function is not required for hyperthermia-enhanced cytotoxicity of cisplatin. Int. J. Hyperthermia 17(4), 337-346 (2001).
125. Peng CL, Tsai HM, Yang SJ et al. Development of thermosensitive poly(N-isopropylacrylamide-co-((2-dimethylamino) ethyl methacrylate))-based nanoparticles for controlled drug release. Nanotechnology 22(26), 265608 (2011).
126. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): Induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2(3), 209-221 (2011).
127. Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R. Bortezomib: Understanding the mechanism of action. Mol. Cancer Ther. 10(11), 2029-2030 (2011).
128. Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Semin. Hematol. 49(3), 228-242 (2012).
129. Johnson VA, Singh EK, Nazarova LA, Alexander LD, McAlpine SR. Macrocyclic inhibitors of Hsp90. Curr. Top. Med. Chem. 10(14), 1380-1402 (2010).
130. Balogh G, Maulucci G, Gombos I et al. Heat stress causes spatially-distinct membrane re-modelling in K562 leukemia cells. PLoS One 6(6), e21182 (2011).
131. Dempsey NC, Ireland HE, Smith CM, Hoyle CF, Williams JHH. Heat shock protein translocation induced by membrane fluidization increases tumor-cell sensitivity to chemotherapeutic drugs. Cancer Lett. 296(2), 257-267 (2010).
132. Adachi S, Kokura S, Okayama T et al. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int. J. Hyperthermia 25(3), 210-219 (2009).
133. Ishikawa T, Kokura S, Sakamoto N et al. Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Int. J. Hyperthermia 28(7), 597-604 (2012).
134. Rusak G, Gutzeit HO, Ludwig-Muller J. Effects of structurally related flavonoids on hsp gene expression in human promyeloid leukaemia cells. Food Technol. Biotechnol. 40(4), 267-273 (2002).
135. Grant S. Enhancing proteotoxic stress as an anticancer strategy. Oncotarget 2(4), 284-286 (2011).
136. Yavelsky V, Vais O, Piura B, Wolfson M, Rabinovich A, Fraifeld V. The role of Hsp90 in cell response to hyperthermia. J. Therm. Biol. 29(7-8), 509-514 (2004).
137. Helmbrecht K, Zeise E, Rensing L. Chaperones in cell cycle regulation and mitogenic signal transduction: A review. Cell Prolif. 33(6), 341-365 (2000).
138. Devi SV, Prakash T. Kinetics of cisplatin release by in vitro using poly(d,l-lactide) coated Fe3O4 nanocarriers. IEEE Trans. NanoBiosci. 12(1), 60-63 (2013).
139. Wagstaff AJ, Brown SD, Holden MR et al. Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorg. Chim. Acta 393, 328-333 (2012).
140. Falqueiro AM, Primo FL, Morais PC, Mosiniewicz-Szablewska E, Suchocki P, Tedesco AC. Selol-loaded magnetic nanocapsules: A new approach for hyperthermia cancer therapy. J. Appl. Phys. 109(7), p07B306 (2011).
141. Likhitkar S, Bajpai AK. Magnetically controlled release of cisplatin from superparamagnetic starch nanoparticles. Carbohydr. Polym. 87(1), 300-308(2012).
142. Kavaz D, Odabas S, Guven E, Demirbilek M, Denkbas EB. Bleomycin loaded magnetic chitosan nanoparticles as multifunctional nanocarriers. J. Bioact. Compatible Polym. 25(3), 305-318 (2010).
143. Kumari S, Singh RP. Glycolic acid-functionalized chitosan-CO3O4-Fe3O4 hybrid magnetic nanoparticles-based nanohybrids scaffolds for drug delivery and tissue engineering. J. Mater. Sci. 48, 1524-1532 (2013).
144. Viota JL, Carazo A, Munoz-Gamez JA et al. Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation. Mater. Sci. Eng. C Mater. Biol. Appl. 33(3), 1183-1192 (2013).
145. Naik S, Carpenter EE. Poly(d,l-lactide-co-glycolide) microcomposite containing magnetic iron core nanoparticles as a drug carrier. J. Appl. Phys. 103(7), 07A313 (2008).
146. Jiang Z, Chen BA, Xia GH et al. The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells. Int. J. Nanomedicine 4(1), 107-114 (2009).
147. Taylor A, Krupskaya Y, Kramer K et al. Cisplatin-loaded carbon-encapsulated iron nanoparticles and their in vitro effects in magnetic fluid hyperthermia. Carbon 48(8), 2327-2334 (2010).
148. Babincová M, Altanerova V, Altaner C, Bergemann C, Babinec P. In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia. IEEE Trans. Nanobiosci. 7(1), 15-19 (2008).
149. Kettering M, Zorn H, Bremer-Streck S et al. Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications. Phys. Med. Biol. 54(17), 5109-5121 (2009).
150. Cheng K, Peng S, Xu CJ, Sun S. Porous hollow Fe3O4 nanoparticles for targeted delivery and controlled release of cisplatin. J. Am. Chem. Soc. 131(30), 10637-10644 (2009).
151. Lee JS, Rodríguez-Luccioni HL, Méndez J et al. Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis diamminedichloroplatinum. J. Nanosci. Nanotechnol. 11(5), 4153-4157 (2011).
152. Alvarez-Berríos MP, Castillo A, Méndez J, Soto O, Rinaldi C, Torres-Lugo M. Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity. Int. J. Nanomedicine 8, 1003-1013 (2013).
153. Rodríguez-Luccioni HL, Latorre-Esteves M, Méndez-Vega J et al. Enhanced reduction in cell viability by hyperthermia induced by magnetic nanoparticles. Int. J. Nanomedicine 6, 373-380 (2011).
154. Brusentsov NA, Brusentsova TN, Filinova EY et al. Magnetohydrodynamic thermochemotherapy and MRI of mouse tumors. J. Magn. Magn. Mater. 311(1), 176-180 (2007).
155. Brusentsov NA, Polyanskii VA, Pirogov YA et al. Antitumor effects of the combination of magnetohydrodynamic thermochemotherapy and magnetic resonance tomography. Pharm. Chem. J. 44(6), 291-295 (2010).
156. Li FR, Yan WH, Guo YH, Qi H, Zhou HX. Preparation of carboplatin-Fe@C- loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer. Int. J. Hyperthermia 25(5), 383-391 (2009).
157. Ito A, Saito H, Mitobe K et al. Inhibition of heat shock protein 90 sensitizes melanoma cells to thermosensitive ferromagnetic particle-mediated hyperthermia with low Curie temperature. Cancer Sci. 100(3), 558-564 (2009).
158. Ren YY, Zhang HJ, Chen BA et al. Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int. J. Nanomedicine 7, 2261-2269 (2012).
159. Kulshrestha P, Gogoi M, Bahadur D, Banerjee R. In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia. Colloids Surf. B Biointerfaces 96, 1-7 (2012).
160. Alvarez-Berrios MP, Castillo A, Rinaldi C, Torres-Lugo M. Magnetic fluid hyperthermia enhances bortezomib cytotoxicity in sensitive and resistant cancer cell lines. Int. J. Nanomedicine (2013) (In Press).
161. Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann. Surg. Oncol. 10(4), 463-468 (2003).
162. Takagi M, Sakata K, Someya M et al. The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization. Strahlenther. Onkol. 188(3), 255-261 (2012).
163. Vertrees RA, Das GC, Popov VL et al. Synergistic interaction of hyperthermia and gemcitabine in lung cancer. Cancer Biol. Ther. 4(10), 1144-1153 (2005).
164. Chen F, Rezavi R, Wang CC, Harrison LE. Proteasome inhibition potentiates the cytotoxic effects of hyperthermia in HT-29 colon cancer cells through inhibition of heat shock protein 27. Oncology 73(1-2), 98-103 (2007).
165. Chen F, Wang CC, Kim E, Harrison LE. Hyperthermia in combination with oxidative stress induces autophagic cell death in HT-29 colon cancer cells. Cell Biol. Int. 32(7), 715-723 (2008).
166. Razavi R, Harrison LE. Thermal sensitization using induced oxidative stress decreases tumor growth in an in vivo model of hyperthermic intraperitoneal perfusion. Ann. Surg. Oncol. 17(1), 304-311 (2010).
167. Wang CC, Chen F, Kim E, Harrison LE. Thermal sensitization through ROS modulation: A strategy to improve the efficacy of hyperthermic intraperitoneal chemotherapy. Surgery 142(3), 384-392 (2007).
168. Eppink B, Krawczyk PM, Stap J, Kanaar R. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int. J. Hyperthermia 28(6), 509-517 (2012).
169. Miyagawa T, Saito H, Minamiya Y et al. Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature. Int. J. Clin. Oncol. doi:10.1007/s10147-013-0606-x (2013) (Epub ahead of print).